 |
36 Diseases |  |
5 Trials |
|
5 Trials |  |
637 News |  |
| «12345678910» |
- ||| Olysio (simeprevir) / J&J, Medivir
Enrollment change: COMMIT: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (clinicaltrials.gov) - Mar 7, 2015
P2, N=250, Recruiting, Sponsor: Janssen-Cilag International NV
N=110 --> 250
- || samatasvir (IDX719) / Merck (MSD)
Trial primary completion date: Samatasvir (IDX719) in Combinations With Simeprevir and/or TMC647055/Ritonavir With or Without Ribavirin for 12 Weeks in Participants With Chronic Hepatitis C Infection (MK-1894-005) (clinicaltrials.gov) - Mar 3, 2015
P2, N=143, Active, not recruiting, Sponsor: Merck Sharp & Dohme Corp.
N=110 --> 250 Trial primary completion date: Jun 2014 --> Apr 2015
- ||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Feb 6, 2015
P2, N=63, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Trial primary completion date: Jun 2014 --> Apr 2015 Recruiting --> Active, not recruiting
- |||| Olysio (simeprevir) / J&J, Medivir
Enrollment open: COMMIT: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (clinicaltrials.gov) - Feb 5, 2015
P2, N=110, Recruiting, Sponsor: Janssen-Cilag International NV
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
Enrollment change, Trial primary completion date: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Jan 30, 2015
P2, N=45, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Not yet recruiting --> Recruiting N=69 --> 45 | Trial primary completion date: May 2016 --> Oct 2015
- ||||| Olysio (simeprevir) / J&J, Medivir
New P2 trial: ACCORDION-1: Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection (clinicaltrials.gov) - Jan 28, 2015
P2, N=90, Recruiting, Sponsor: Janssen Research & Development, LLC
- | Olysio (simeprevir) / J&J, Medivir
Enrollment open, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 26, 2015
P3, N=40, Recruiting, Sponsor: Janssen R&D Ireland
N=69 --> 45 | Trial primary completion date: May 2016 --> Oct 2015 Not yet recruiting --> Recruiting
- |||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion, Trial primary completion date, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Jan 26, 2015
P2a, N=90, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014
- |||| Olysio (simeprevir) / J&J, Medivir
Enrollment open, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Jan 15, 2015
P2, N=60, Recruiting, Sponsor: Janssen-Cilag International NV
Active, not recruiting --> Completed | Trial primary completion date: Dec 2014 --> Sep 2014 Not yet recruiting --> Recruiting
- |||| Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (clinicaltrials.gov) - Jan 13, 2015
P3, N=232, Active, not recruiting, Sponsor: Janssen-Cilag International NV
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2014 --> Aug 2015
- velpatasvir (GS-5816) / Gilead, Daklinza (daclatasvir) / BMS, Exviera (dasabuvir) / AbbVie
Clinical: GEHEP: Efficacy and Safety of Therapy Against HCV Based on Direct-acting Antivirals in Real-life Conditions (clinicaltrials.gov) - Jan 7, 2015
P=N/A, N=210, Recruiting, Sponsor: Valme University Hospital
- | Olysio (simeprevir) / J&J, Medivir
Enrollment open: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Jan 2, 2015
P4, N=40, Recruiting, Sponsor: SC Liver Research Consortium, LLC
Trial primary completion date: Oct 2014 --> Aug 2015 Not yet recruiting --> Recruiting
- ||||||| Olysio (simeprevir) / J&J, Medivir
Trial completion: An Efficacy, Pharmacokinetics, Safety and Tolerability Study of TMC435 as Part of a Treatment Regimen for Hepatitis C-Infected Patients (clinicaltrials.gov) - Dec 17, 2014
P3, N=458, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Olysio (simeprevir) / J&J, Medivir
Enrollment change, Trial withdrawal, Trial primary completion date, Metastases: A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C (clinicaltrials.gov) - Nov 25, 2014
P4, N=0, Withdrawn, Sponsor: University of California, San Francisco
Active, not recruiting --> Completed N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2015 --> Nov 2014
- ||||| Olysio (simeprevir) / J&J, Medivir
New P2 trial, Combination therapy: An Efficacy and Safety Study of a 8 or 12-Week Treatment Regimen of Simeprevir in Combination With Sofosbuvir in Treatment-Naive and Experienced Participants With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Oct 30, 2014
P2, N=60, Not yet recruiting, Sponsor: Janssen-Cilag International NV
- ||||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed: A Study of TMC435 Plus Pegylated Interferon Alfa-2a and Ribavirin in Participants With Chronic HCV Infection (clinicaltrials.gov) - Oct 23, 2014
P3, N=228, Active, not recruiting, Sponsor: Janssen-Cilag International NV
N=20 --> 0 | Not yet recruiting --> Withdrawn | Trial primary completion date: Sep 2015 --> Nov 2014 Recruiting --> Active, not recruiting
- ||||| Olysio (simeprevir) / J&J, Medivir
New P2 trial: COMMIT: A Study to Assess the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Participants (clinicaltrials.gov) - Oct 20, 2014
P2, N=110, Not yet recruiting, Sponsor: Janssen-Cilag International NV
- | Olysio (simeprevir) / J&J, Medivir
New P2 trial: An Efficacy, Safety and Pharmacokinetics Study of Simeprevir, Daclatasvir and Sofosbuvir in Participants With Chronic Hepatitis C Virus Genotype 1 or 4 Infection and Decompensated Liver Disease (clinicaltrials.gov) - Oct 15, 2014
P2, N=40, Recruiting, Sponsor: Janssen Research & Development, LLC
- ||| Olysio (simeprevir) / J&J, Medivir
New P3 trial, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Oct 4, 2014
P3, N=40, Not yet recruiting, Sponsor: Janssen R&D Ireland
- | Olysio (simeprevir) / J&J, Medivir
New P2 trial, Combination therapy: Simeprevir in Combination With Sofosbuvir in Treatment-Na (clinicaltrials.gov) - Oct 2, 2014
P2, N=30, Not yet recruiting, Sponsor: Peter J. Ruane, M.D.
- |||| Olysio (simeprevir) / J&J, Medivir
Enrollment open: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Oct 2, 2014
P2, N=69, Recruiting, Sponsor: Janssen Scientific Affairs, LLC
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants (clinicaltrials.gov) - Sep 30, 2014
P1, N=32, Completed, Sponsor: Janssen Research & Development, LLC
Not yet recruiting --> Recruiting Recruiting --> Completed
- ||| Olysio (simeprevir) / J&J, Medivir
New P3 trial, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Subjects With Chronic Genotype 4 Hepatitis C Virus Infection (clinicaltrials.gov) - Sep 28, 2014
P3, N=40, Not yet recruiting, Sponsor: Janssen Infectious Diseases BVBA
- | Olysio (simeprevir) / J&J, Medivir
Enrollment closed: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Sep 9, 2014
P2, N=35, Active, not recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Completed Recruiting --> Active, not recruiting
- | samatasvir (IDX719) / Merck (MSD)
Trial completion: Drug-Drug Interaction Between IDX719, Simeprevir, TMC647055 and Ritonavir When Administered in Combination in Healthy Participants (MK-1894-007) (clinicaltrials.gov) - Aug 29, 2014
P1, N=34, Completed, Sponsor: Idenix Pharmaceuticals
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- | samatasvir (IDX719) / Merck (MSD)
Trial completion, Trial primary completion date: Study to Evaluate Drug-Drug Interaction Between IDX719 and Simeprevir in Healthy Participants (MK-1894-004) (clinicaltrials.gov) - Aug 29, 2014
P1, N=42, Completed, Sponsor: Idenix Pharmaceuticals
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jul 2013
- || Olysio (simeprevir) / J&J, Medivir
Trial primary completion date: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Aug 15, 2014
P2, N=69, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
Active, not recruiting --> Completed | Trial primary completion date: Apr 2013 --> Jul 2013 Trial primary completion date: Jul 2015 --> May 2016
- | Olysio (simeprevir) / J&J, Medivir
Enrollment change: A Study of Pharmacokinetics, Efficacy, Safety, Tolerability, of the Combination of Simeprevir (TMC435), Daclatasvir (BMS-790052), and Ribavirin (RBV) in Patients With Recurrent Chronic Hepatitis C Genotype 1b Infection After Orthotopic Liver Transplantation (clinicaltrials.gov) - Aug 15, 2014
P2, N=30, Recruiting, Sponsor: Janssen R&D Ireland
Trial primary completion date: Jul 2015 --> May 2016 N=40 --> 30
- Olysio (simeprevir) / J&J, Medivir
New P4 trial: SMV + SOF With/Without RBV for IFN-II Patients With CHC (clinicaltrials.gov) - Aug 12, 2014
P4, N=0, Not yet recruiting, Sponsor: SC Liver Research Consortium, LLC
- | Olysio (simeprevir) / J&J, Medivir
New P4 trial, Metastases: A Study of the Safety and Effectiveness of Simeprevir and Sofosbuvir for Patients With HIV and Hepatitis C (clinicaltrials.gov) - Aug 1, 2014
P4, N=20, Not yet recruiting, Sponsor: University of California, San Francisco
- ||| TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Jul 27, 2014
P2a, N=90, Active, not recruiting, Sponsor: Janssen R&D Ireland
N=40 --> 30 Recruiting --> Active, not recruiting
- || TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial primary completion date, Combination therapy: A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus (clinicaltrials.gov) - Jun 27, 2014
P2a, N=86, Recruiting, Sponsor: Janssen R&D Ireland
Recruiting --> Active, not recruiting Trial primary completion date: Aug 2015 --> Jan 2015
- | Olysio (simeprevir) / J&J, Medivir
New P4 trial: The SIM-SOF Trial for Hepatitis C (clinicaltrials.gov) - Jun 22, 2014
P4, N=82, Active, not recruiting, Sponsor: Center For Hepatitis C, Atlanta, GA
- ||||| Olysio (simeprevir) / J&J, Medivir
New P2 trial: An Efficacy and Safety Study of Simeprevir and Sofosbuvir With and Without Ribavirin in Participants With Recurrent Genotype 1 Hepatitis C Post-Orthotopic Liver Transplant (clinicaltrials.gov) - Jun 18, 2014
P2, N=69, Not yet recruiting, Sponsor: Janssen Scientific Affairs, LLC
- Olysio (simeprevir) / J&J, Medivir
Enrollment open: A Study to Examine the Pharmacokinetics, Safety and Tolerability of Multiple Oral Doses of TMC435 in Healthy Chinese Participants (clinicaltrials.gov) - Jun 18, 2014
P1, N=32, Recruiting, Sponsor: Janssen Research & Development, LLC
Trial primary completion date: Aug 2015 --> Jan 2015 Not yet recruiting --> Recruiting
- | GSK 2336805 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK2336805 Alone and With the Co-administration of TMC435 in Healthy Japanese Participants. (clinicaltrials.gov) - Jun 18, 2014
P1, N=48, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- | Olysio (simeprevir) / J&J, Medivir
Phase classification, Combination therapy: PILLAR: A Study of TMC435 in Combination With Pegylated Interferon AlpFa-2a and Ribavirin in Patients Infected With Genotype 1 Hepatitis C Virus Who Never Received Treatment (clinicaltrials.gov) - Jun 17, 2014
P2b, N=386, Completed, Sponsor: Tibotec Pharmaceuticals, Ireland
Active, not recruiting --> Completed Phase classification: P2 --> P2b
- ||||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis (clinicaltrials.gov) - Jun 5, 2014
P3, N=300, Active, not recruiting, Sponsor: Janssen Infectious Diseases BVBA
Phase classification: P2 --> P2b Recruiting --> Active, not recruiting
- ||||| Olysio (simeprevir) / J&J, Medivir
Enrollment closed, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis (clinicaltrials.gov) - Jun 5, 2014
P3, N=100, Active, not recruiting, Sponsor: Janssen Infectious Diseases BVBA
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- |||||| Olysio (simeprevir) / J&J, Medivir
Enrollment open, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis (clinicaltrials.gov) - May 22, 2014
P3, N=300, Recruiting, Sponsor: Janssen Infectious Diseases BVBA
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- |||||| Olysio (simeprevir) / J&J, Medivir
Enrollment open, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis (clinicaltrials.gov) - May 22, 2014
P3, N=100, Recruiting, Sponsor: Janssen Infectious Diseases BVBA
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial primary completion date, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - May 14, 2014
P1, N=24, Completed, Sponsor: Janssen R&D Ireland
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2014 --> Apr 2014
- TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion date, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - May 14, 2014
P1, N=24, Completed, Sponsor: Janssen R&D Ireland
Trial primary completion date: Jun 2014 --> Apr 2014 Trial completion date: Jun 2014 --> Apr 2014
- | TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Trial completion, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - May 14, 2014
P1, N=24, Completed, Sponsor: Janssen R&D Ireland
Trial completion date: Jun 2014 --> Apr 2014 Recruiting --> Completed
- |||| Olysio (simeprevir) / J&J, Medivir, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial primary completion date, Combination therapy: TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINF?-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINF?-2a and Ribavirin Therapy (clinicaltrials.gov) - May 11, 2014
P3, N=766, Completed, Sponsor: Janssen R&D Ireland
Recruiting --> Completed Trial primary completion date: Mar 2014 --> Apr 2014
- ||||||| Olysio (simeprevir) / J&J, Medivir, Incivek (telaprevir) / J&J, Vertex, Mitsubishi Tanabe
Trial completion, Combination therapy: TMC435HPC3001 - An Efficacy, Safety and Tolerability Study for TMC435 vs Telaprevir in Combination With PegINF?-2a and Ribavirin in Chronic Hepatitis C Patients Who Were Null or Partial Responders to Prior PegINF?-2a and Ribavirin Therapy (clinicaltrials.gov) - May 11, 2014
P3, N=766, Completed, Sponsor: Janssen R&D Ireland
Trial primary completion date: Mar 2014 --> Apr 2014 Active, not recruiting --> Completed
- TMC647055 / J&J, Olysio (simeprevir) / J&J, Medivir
Enrollment change, Combination therapy: A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of TMC647055 in Combination With Ritonavir (Part 1) and the Co-administration of TMC435, TMC647055 and Ritonavir (Part 2) in Healthy Japanese Participants (clinicaltrials.gov) - May 8, 2014
P1, N=24, Recruiting, Sponsor: Janssen R&D Ireland
Active, not recruiting --> Completed N=48 --> 24
- |||| Daklinza (daclatasvir) / BMS
Trial completion, Combination therapy: Study of Daclatasvir (BMS-790052) and Simeprevir (TMC435) in Patients With Genotype 1 Chronic Hepatitis C Virus (clinicaltrials.gov) - May 4, 2014
P2, N=168, Completed, Sponsor: Bristol-Myers Squibb
N=48 --> 24 Active, not recruiting --> Completed
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Chronic Hepatitis C Virus Infection Without Cirrhosis (clinicaltrials.gov) - Apr 13, 2014
P3, N=300, Not yet recruiting, Sponsor: Janssen Infectious Diseases BVBA
- |||||||||| Olysio (simeprevir) / J&J, Medivir
New P3 trial, Combination therapy: Efficacy and Safety Study of Simeprevir in Combination With Sofosbuvir in Participants With Genotype 1 Chronic Hepatitis C Virus Infection and Cirrhosis (clinicaltrials.gov) - Apr 13, 2014
P3, N=100, Not yet recruiting, Sponsor: Janssen Infectious Diseases BVBA